Worldwide, there are nearly 10 million new cases of dementia annually, of which Alzheimer's disease (AD) is the most common. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research
28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
A panel of possible CSF biomarkers for AD has been identified using proteomic methods. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Whether initiation of statins could increase survival free of dementia and disability in adults aged ≥75 years is unknown. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
Utilization and costs for patients with AD were higher compared to controls and were substantially higher for patients with both AD and co-morbid diseases commonly targeted for disease management. 5 key findings →
Participants: 1,366 Evidence: low
Full summary, score breakdown and related studies → Original source
The authors identified several factors, including receipt of mechanical ventilation, which were significantly associated with increased long-term mortality for survivors of severe sepsis. 5 key findings →
Participants: 2,727 Evidence: low
Full summary, score breakdown and related studies → Original source
The burden of dementia in Korea is expected to considerably increase alongside the elderly population in the future. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Using pre-trained language models can improve AD prediction. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Metformin, a diabetes drug with anti-aging cellular responses, has complex actions that may alter dementia onset. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We determined the effects of distraction on gait in healthy elderly subjects and Alzheimer's disease (AD) patients. 5 key findings →
Participants: 20 Evidence: low
Full summary, score breakdown and related studies → Original source
Conductance to outflow of CSF was measured in a prospective study of 80 patients with normal pressure hydrocephalus. 3 key findings →
Participants: 80 Evidence: low
Full summary, score breakdown and related studies → Original source
Physical performance speed was associated with executive function after adjusting for age, sex, and age-related factors in sedentary older adults with aMCI. 5 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
We studied 30 necropsy cases of vascular dementia with a lacunar state. 5 key findings →
Participants: 30 Evidence: low
Full summary, score breakdown and related studies → Original source
Under normal conditions, vivid dream mentation combined with skeletal muscle paralysis characterizes rapid eye movement sleep. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Brains of 42 individuals between the ages of 4 and 29 were examined with antibodies (AT8, 4G8) and silver stains for the presence of intraneuronal and extracellular protein aggregates associated with Alzheimer's disease. 2 key findings →
Participants: 42 Evidence: low
Full summary, score breakdown and related studies → Original source
Phosphodiesterases (PDEs) are enzymes involved in the homeostasis of both cAMP and cGMP. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
47/100
Multiple sclerosis remains one of the most common causes of neurological disability in the young adult population (aged 18-40 years). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
With recent findings connecting the Epstein-Barr virus to an increased risk of multiple sclerosis and growing concerns regarding the neurological impact of the coronavirus pandemic, we examined potential links between viral exposures and neurodegenerative disease risk. 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Cholinergic neuron loss is a cardinal feature of Alzheimer disease. 1 key finding →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source
We confirm that variation in/near APOE/TOMM40 (P = 6 × 10(-14)) alters PCA risk, but with smaller effect than for typical AD (PCA: odds ratio [OR] = 2.03, typical AD: OR = 2.83, P = .0007). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Trisomy of chromosome 21, the cause of Down syndrome (DS), is the most commonly occurring genetic cause of Alzheimer’s disease (AD). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Higher HOMA-IR was associated with higher sAβPPβ and Aβ42 . 4 key findings →
Participants: 70 Evidence: low
Full summary, score breakdown and related studies → Original source
The predictive value of Aβ42 was highly affected by the type of collection tube used. 5 key findings →
Participants: 1,966 Evidence: low
Full summary, score breakdown and related studies → Original source
Mean +/- SD CSF NFL levels were increased in patients with FTD (1442 +/- 1183 pg/mL; p < 0.05) and LAD (1006 +/- 727 pg/mL; p < 0.001) compared with control subjects (241 +/- 166 pg/mL) and in LAD compared with EAD (498 +/- 236 pg/mL; p < 0.05), and tended to be increased in FTD compared with EAD. 5 key findings →
Participants: 18 Evidence: low
Full summary, score breakdown and related studies → Original source
Previous trials have shown promising effects of intranasally administered insulin for adults with Alzheimer's disease dementia (AD) or amnestic mild cognitive impairment (MCI). 5 key findings →
Participants: 20 Evidence: low
Full summary, score breakdown and related studies → Original source
Large studies (e.g. UK Biobank) are increasingly used for GWAS and Mendelian randomization (MR) studies. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →